plasmid amplification and purification applications
Plasmid propagation and purification of DNA
The product will be shipped in the desired
solution and at the required concentration,
certifications according to its specifications
production group that best suits your needs
according to your application, and the table
transfection of cellular culture and tissues
below to read about the group specifications. specifications
spectrophotometry at 260, 280 and 310 nmDNA concentration
spectrophotometry at 260 nmplasmid homogeneity
densitometry in agarose gelgenomic DNA contamination
densitometry in agarose gelRNA contamination
densitometry in agarose gelendotoxin (LPS) content
enzymatic restriction (1 enzyme)plasmid identity
automatic sequencing (up to 600 bp)plasmid identity
Any of the optional analysis can be requested separately
1 Production batches smaller than 10 mg are shipped with a qualitative product analysis in agarose gel and the
quantitative result from the DNA spectrophotometric determination.
Production batches larger than 10 mg are shipped with the corresponding analysis following the specifications
2 No RNase or any other animal-derived enzymes are used in group 3 production processes. 3 These scales are valid for plasmids producing more than 200 copies per cell (high copy number). For low copy
number plasmids, the yield is from 3 to 5 times lower.
4 Determined through capillary electrophoresis. Contact us for other applications or specific needs:
resistance to antibiotics different from kanamycin or ampicillin
host cells different from Escherichia coliplasmid design and construction modification and mutagenesis In case you need to modify your plasmid functionalities, we can introduce or eliminate specific sequences. We can also introduce directed, random or multiple mutations into plasmid molecules and, if you wish, sequence the mutated fragment. design and construction Following your directions, we can design and construct exclusive plasmids suited for the following applications:
specific propagation in different microorganisms
work with microbial cells creation of recombinant strains Strain and plasmid combination to create cell lines with specific properties. electrocompetent cells From the selected cellular strain, we will create electrocompetent cells ready to be transformed by electroporation. microbial cell transformation Transformation of competent cells with the selected plasmid. microbial cultures Microorganisms within biosecurity level 1 or 2. Contact us for any doubt about the biosecurity level of your microorganism.
Cultures and fermentations up to a volume of 5 L of microorganisms like:
Contact us if you are interested in larger scale or other microorganism types. sample characterization PCR (Polymerase Chain Reaction) Analysis of the presence/absence of desired DNA sequences in a sample through the amplification by the polymerase chain reaction. RFLP (Restriction Fragment Length Polymorphism) Analysis of the obtained fragments following enzymatic restriction. We will make a simple or multiple sample digestion, perform an electrophoresis and detect the resulting fragments. isoform analysis Determination of the topoisomer homogeneity in a plasmid sample. We will perform an electrophoresis on the plasmid preparation, followed by a densitometry analysis to discriminate and quantify the different topoisomers. total protein content Total protein load analysis in a sample through the bicinchoninic acid assay (BCA). endotoxin content (LPS) Analysis of the endotoxin content in a sample through the chromogenic LAL (Limulus Amebocyte Lisate) test. sequencing Reading of the nucleotide sequence of a DNA fragment through automatic sequencing. customized projects technology transfer product combinations customized applications collaborations consulting
Home 1 > Safety 2 > Recalls, Market Withdrawals, & Safety Alerts 3 Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as aservice to consumers, the media, and other interested parties. FDA does not endorse either the product or the Bristol-Myers Squibb Initiates a Nationwide Voluntary Recall of Coumadi
IV Levetiracetam For Treatment of Cluster Headachein the ClinicJohn Claude Krusz PhD MD, Jane Cagle LVN, Dan Daniel RPHCASE 4: GF, a 41 year old businessman had reonset of cluster headache episodes, leftsided, 2 months prior to being seen. He was having 3-6 episodes per day, mostly at night. 4 years prior, he had first onset of cluster headaches lasting almost 6 weeks. IV INTRODUCTION: Levetir